{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(5)"],"submitter":["Kong N"],"funding":["Changchun GeneScience Pharmaceutical Co., Ltd."],"pubmed_abstract":["Introduction
Firsekibart, an anti-interleukin (IL)-1β monoclonal antibody, has demonstrated more sustained control of gout flares compared with compound betamethasone in previous clinical studies. This study evaluated the efficacy and safety of firsekibart versus etoricoxib for the treatment of frequent gout flares.Methods
In this phase 2, randomized, open-label, active-controlled, multicenter study (NCT05936268), adults with gout according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2015 criteria experiencing frequent flares (≥ 2 flares within 12 months pre-screening) were randomized (1:1) to receive either a single subcutaneous injection of firsekibart 200 mg, or once-daily oral etoricoxib 120 mg administered until pain remissi"],"journal":["Rheumatology and therapy"],"pagination":["975-990"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12450154"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial."],"pmcid":["PMC12450154"],"pubmed_authors":["Kong N","Zou H","Yang L","Xu Q","Li R","Yu J","Mao L","Xue Y","Yuan F","Hu J","Guo H","Zhang X","Gou W","Wei H","Qian L","Duan X","Luo T"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial.","description":"Introduction
Firsekibart, an anti-interleukin (IL)-1β monoclonal antibody, has demonstrated more sustained control of gout flares compared with compound betamethasone in previous clinical studies. This study evaluated the efficacy and safety of firsekibart versus etoricoxib for the treatment of frequent gout flares.Methods
In this phase 2, randomized, open-label, active-controlled, multicenter study (NCT05936268), adults with gout according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2015 criteria experiencing frequent flares (≥ 2 flares within 12 months pre-screening) were randomized (1:1) to receive either a single subcutaneous injection of firsekibart 200 mg, or once-daily oral etoricoxib 120 mg administered until pain remissi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-03T16:52:14.598Z","creation":"2026-04-29T03:13:15.358Z"},"accession":"S-EPMC12450154","cross_references":{"pubmed":["40833487"],"doi":["10.1007/s40744-025-00790-6"]}}